Cargando...
Distinct gene expression signatures characterize strong clinical responders vs non-responders to Canakinumab in children with sJIA
BACKGROUND: Canakinumab is a human anti-IL-1β blocking agent that effectively neutralizes IL-1β mediated signaling for treatment of systemic juvenile idiopathic arthritis (sJIA). While many patients have dramatic clinical response to IL-1 blockade, approximately one-third fail to respond, but there...
Guardado en:
| Publicado en: | Arthritis Rheumatol |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8238800/ https://ncbi.nlm.nih.gov/pubmed/33452871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.41640 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|